Key result
Percutaneous aortic balloon valvuloplasty reduced mean aortic valve gradients from 49 mm Hg to 30 mm Hg and increased mean aortic valve area from 0.59 cm2 to 0.90 cm2, with a 12-month mortality rate of 45%.
Observational (n=33)
No
PABV provides significant immediate hemodynamic improvement and serves as a viable palliative or bridging therapy to TAVI in high-risk, inoperable elderly patients with severe aortic stenosis, despite high long-term mortality.
A total of 33 patients with severe aortic stenosis undergoing percutaneous aortic balloon valvuloplasty (PABV) for bridging or palliative therapy were reviewed; the emerging treatment patterns for this procedure are described. Longitudinal data suggest that PABV provides a significant reduction in peak and mean aortic valve gradients with > 12-month survival for more than half of observed patients. This supports the current application of PABV, which is currently limited to palliative care and bridging therapy to more definitive forms of future treatment, including transcatheter aortic valve implantation.
No takes yet. Share an insight, caveat, or question.
Gorges et al. (2011) conducted an observational in Severe degenerative aortic stenosis (n=33). Percutaneous aortic balloon valvuloplasty (PABV) was evaluated on Aortic valve gradients, valve area, and survival. Percutaneous aortic balloon valvuloplasty reduced mean aortic valve gradients from 49 mm Hg to 30 mm Hg and increased mean aortic valve area from 0.59 cm2 to 0.90 cm2, with a 12-month mortality rate of 45%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: